2-Methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine → (R)-4-(3-Hydroxypyrrolidin-1-yl)-3-(2-methylpyrimidin-5-yl)-N-(4-(trifluoromethoxy)phenyl)benzamide

Participants

Reaction Steps

The title compound was prepared in an analogous fashion to that described in Example 1 using (R)-3-bromo-4-(3-hydroxypyrrolidin-1-yl)-N-(4-(trifluoromethoxy)phenyl)benzamide (Stage 2.1) and 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine to afford a white solid. UPLC-MS (condition 1) tR=2.46 min, m/z=459.1-460.1 [M+H]+, m/z=457.2-458.2 [M−H]−; 1H-NMR (400 MHz, DMSO-d6) δ ppm 1.76 (d, J=3.91 Hz, 1H) 1.82-1.93 (m, 1H) 2.65-2.72 (m, 1H) 2.68 (s, 3H) 3.00-3.11 (m, 2H) 3.18-3.27 (m, 1H) 4.17-4.25 (m, 1H) 4.86 (d, J=3.67 Hz, 1H) 6.96 (d, J=8.80 Hz, 1H) 7.33 (d, J=8.56 Hz, 2H) 7.81 (d, J=2.20 Hz, 1H) 7.83-7.88 (m, 2H) 7.92 (dd, J=8.80, 2.20 Hz, 1H) 8.73 (s, 2H) 10.08 (s, 1H).

Provenance & Evidence